Astellas Join Forces with AviadoBio for AVB-101 Gene Therapy Targeting Frontotemporal Dementia and Other Indications
Shots:
- Astellas & AviadoBio have entered into an exclusive option & licensing agreement for AVB-101, currently under P-I/II clinical evaluation to treat frontotemporal dementia with progranulin mutations (FTD-GRN)
- The agreement offers Astellas with an option to secure exclusive global rights to develop & commercialize AVB-101 for FTD-GRN & other indications in an exchange of $30M upfront, $20M equity as well as ~$2.18B licensing fees & milestones with additional royalties
- AVB-101 (intrathalamic) is a one-time, AAV-based gene therapy being developed to transfer a functional copy of the GRN gene through neuronal networks for optimal distribution to restore progranulin levels in the brain, stopping disease progression
Ref: Astellas | Image: Astellas & AviadoBio
Related News:- Astellas’ Vyloy (Zolbetuximab) Plus Chemotherapy Gains the EC’s Approval for Advanced Gastric and Gastroesophageal Junction Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
